Replies to post #63021 on Biotech Values

[DewDiligence]

ANTICOAGULANT INDEX

[Added entries for Rivaroxaban. Please see
MNTA ‘ReadMeFirst’ for info on M118.]


General
#msg-25160571 Anticoagulant market has large potential (WSJ)
#msg-26899903 Anticoagulant market has large potential (graphic)
#msg-26451612 Venous thromboembolism is a big, big problem (The Lancet)
#msg-18759853 Overview of the new oral anticoagulants
#msg-26701803 Technical overview of traditional anticoagulants


Xarelto/Rivaroxaban
#msg-29662519 Rivaroxaban rationale
#msg-29660864 Rivaroxaban bests Lovenox in VTE prevention (knee)
#msg-25147464 Rivaroxaban bests Lovenox in VTE prevention (hip)
#msg-24337258 Bayer plans 50,000(!)-patient study


Apixaban
#msg-19134406 PFE, BMY ink $1B collaboration
#msg-21044973 Apixaban non-inferior to Warfarin in phase-2


Pradaxa/Dabigatran
#msg-27956748 Pradaxa approved for VTE prevention in EU
#msg-26086079 BI completes enrollment of huge AF trial
#msg-25152872 BI starts phase-2 in ACS
#msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention


Miscellaneous
#msg-27590644 ATI-5923 from ARYX: A safer warfarin?
#msg-10569101 Arixtra bests Lovenox in ACS
#msg-29601951 Ablynx begins Phase-1b of ALX-0081 in PCI
#msg-26298260 Biotinylated Idraparinux causes excess bleeding in AF
#msg-22938795 SNY’s AVE5026, Otamixaban (SR123781 dropped Feb-08)
#msg-27043616 ART-123 from Artisan Pharma
#msg-27187973 Paion’s Solulin completes phase-1
#msg-28742653 Paion acquires flovagatran rights
#msg-29771841 NUVO’s NU172 starts phase-1b
#msg-11669012 Lovenox more cost-effective than heparin?